Sfoglia per Rivista
EVALUATION OF ACCURACY OF "CLLFLOW SCORE" BY AN ESTERNAL VALIDATION MULTICENTER STUDY
2018-01-01 D'Arena, G; Vitale, C; Coscia, M; D'Auria, F; Statuto, T; Valvano, L; Bellesi, S; Topini, G; Panichi, V; Corrente, F; Innocenti, I; Musto, P; Laurenti, L
Ex vivo expansion of hematopoietic cells and their clinical use.
1998-01-01 AGLIETTA M ;BERTOLINI F ;CARLO-STELLA C ;DE VINCENTIIS A ;LANATA L ;LEMOLI RM ;OLIVIERI A ;SIENA S ;ZANON P ;TURA S
Expected number of childhood cancers in Italy from 2001 to 2015
2007-01-01 BAUSSANO I; MAULE MM; DAMA E; DALMASSO P; MOSSO ML; GALZERANO M; F. MERLETTI; MAGNANI C; PASTORE G
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL)
2011-01-01 Barbero D; Drandi D; Lobetti Bodoni C; Bernocco E; Coscia M; Ruggeri M; Boi M; Genuardi E; Monitillo L; Mantoan B; Maffeo C; Barbiero S; Ferrero S; Rossi D; Passera R; Gaidano G; Massaia M; Omedè P; Boccadoro M; Ladetto M
Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines.
1989-01-01 STACCHINI A ;PONZETTO C ;GUERRASIO A ;MARTINOTTI G ;REGE CAMBRIN G ;SCARAVAGLIO P ;ROSSO C ;PIACIBELLO W ;AGLIETTA M ;SAGLIO G
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS (TKIS)
2015-01-01 Sora, F; Autore, F; Alimena, G; Annunziata, M; Avanzini, P; Bocchia, M; Breccia, M; Celesti, F; Chiusolo, P; Crugnola, M; Endri, M; Fava, C; Galimberti, S; Gozzini, A; Iurlo, A; Latagliata, R; Musto, P; Porrini, R; Pregno, R; Cambrin, Gr; Sica, S
[Fanconi-Zinsser's disease associated to Lewandowsky-Lutz's disease (author's transl)]
1981-01-01 LOVISETTO P ;BÜCHI G ;MAIRANO S ;BIARESE V ;ACTIS GC ;ZINA A ;BUNDINO S ;DE MARCHI M
Fattori prognostici nel mieloma multiplo.
1989-01-01 Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede' P; Palumbo A; Pileri A
Feasibility of molecular diagnosis of alpha-thalassemia in the evaluation of microcytosis
1997-01-01 Sivera, P; Roetto, A; Mazza, U; Camaschella, C
Fibrinolytic activity in normal and leukemic myeloid differentiation.
1982-01-01 Ghezzo F; Palumbo A; Pegoraro L
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
2020-01-01 Larocca, Alessandra; Mina, Roberto; Offidani, Massimo; Liberati, Anna Marina; Ledda, Antonio; Patriarca, Francesca; Evangelista, Andrea; Spada, Stefano; Benevolo, Giulia; Oddolo, Daniela; Innao, Vanessa; Cangialosi, Clotilde; Bernardini, Annalisa; Musto, Pellegrino; Amico, Valeria; Fraticelli, Vincenzo; Paris, Laura; Giuliani, Nicola; Falcone, Antonietta Pia; Zambello, Renato; De Paoli, Lorenzo; Romano, Alessandra; Palumbo, Antonio; Montefusco, Vittorio; Hajek, Roman; Boccadoro, Mario; Bringhen, Sara
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY
2014-01-01 Scarfo, L; Quaresmini, G; Ambrosetti, A; Laurenti, L; Rossini, F; Trentin, L; Coscia, M; Orlandi, E; Mannina, D; Torreggiani, A; Rambaldi, A; Semenzato, G; Innocenti, I; Brugiatelli, M; Cuneo, A; Foa, R; Molica, S; Morra, E; Pane, F; Pizzolo, G; Ghia, P
FISH-MLL abnormalities in patients in Acute Myeliodblastic Leukemia and association with FLT3 and MLL internal duplication.
2006-01-01 Giugliano E; Rege-Cambrin G; Scaravaglio P; Diverio D; Serra A; Mancini M; Brunetto V; Ferranti G; Mattioli G; Fava C; Fimognari M; Ulisciani S; Pane F; Lo Coco F; Saglio G.
FOUR-YEAR OUTCOME OF 215 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FRONTLINE: A GIMEMA CML WORKING PARTY ANALYSIS
2014-01-01 Gugliotta, G; Castagnetti, F; Breccia, M; Levato, L; Fava, C; Luciano, L; Zaccaria, A; Rossi, Ar; Usala, E; Gozzini, A; Vigneri, P; Cedrone, M; Tiribelli, M; Abruzzese, E; Avanzini, P; Palandri, F; Soverini, S; Alimena, G; Pane, F; Martinelli, G; Cavo, M; Saglio, G; Baccarani, M; Rosti, G
FOXO TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN CML PATIENTS BY BCR-ABL ONCOGENIC SIGNALLING
2008-01-01 F. Messa; C. Panuzzo; F. Arruga; P. Nicoli; E. Messa; A. Morotti; A. Rotolo; S. Carturan; T. Kalebic; I. Iacobucci; G. Martinelli; E. Bracco; G. Saglio; D. Cilloni
FOXO3 TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN ACUTE MYELOID LEUKEMIA PATIENTS
2008-01-01 Panuzzo C; Arruga F; Messa F; Bracco E; Rotolo A; Nicoli P; Morotti A; Maffè C; Iacobucci I; Martinelli G; Baccarani M; Saglio G; Cilloni D
FOXO3 TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN CML PATIENTS BY BCR-ABL ONCOGENIC SIGNALLING
2008-01-01 Panuzzo C; Messa F; Arruga F; Bernardoni R; Rotolo A; Carturan S; Nicoli P; Morotti A; Marrè C; Iacobucci I; Martinelli G; Baccarani M; Saglio G; Cilloni D
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma
2006-01-01 Foglietta M; Mariani S; Castella B; Coscia M; Boccadoro M; Massaia M
FRONT-LINE THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE, OFATUMUMAB (FC-O2) IN YOUNG (<= 65 YRS) AND FIT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. RESULTS OF THE PROSPECTIVE PHASE 2 GIMEMA STUDY LLC0911
2017-01-01 Mauro, FR; Molica, S; Zaja, F; Piciocchi, A; Ilariucci, F; Coscia, M; Carella, AM; Re, F; Liberati, AM; Tedeschi, A; Gozzetti, A; Cuneo, A; Cortelezzi, A; Baraldi, A; Del Poeta, G; Musolino, C; Battistini, R; De Propris, MS; Della Starza, I; Raponi, S; Ilari, C; Cafforio, L; Nanni, M; Fazi, P; Vignetti, M; Russo, F; Porrazzo, M; Riemma, C; Specchia, G; Neri, A; Guarini, A; Foa, R
Front-line treatment of Philadelphia positive chronic myeloid leukemia withimatinib and interferon-alpha: 5-year outcome
2008-01-01 Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; GIMEMA Working Party on CML
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
EVALUATION OF ACCURACY OF "CLLFLOW SCORE" BY AN ESTERNAL VALIDATION MULTICENTER STUDY | 2018 | D'Arena, G; Vitale, C; Coscia, M; D'Auria, F; Statuto, T; Valvano, L; Bellesi, S; Topini, G; Panichi, V; Corrente, F; Innocenti, I; Musto, P; Laurenti, L | |
Ex vivo expansion of hematopoietic cells and their clinical use. | 1998 | AGLIETTA M ;BERTOLINI F ;CARLO-STELLA C ;DE VINCENTIIS A ;LANATA L ;LEMOLI RM ;OLIVIERI A ;SIENA S ;ZANON P ;TURA S | |
Expected number of childhood cancers in Italy from 2001 to 2015 | 2007 | BAUSSANO I; MAULE MM; DAMA E; DALMASSO P; MOSSO ML; GALZERANO M; F. MERLETTI; MAGNANI C; PASTORE G | |
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) | 2011 | Barbero D; Drandi D; Lobetti Bodoni C; Bernocco E; Coscia M; Ruggeri M; Boi M; Genuardi E; Monitillo L; Mantoan B; Maffeo C; Barbiero S; Ferrero S; Rossi D; Passera R; Gaidano G; Massaia M; Omedè P; Boccadoro M; Ladetto M | |
Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines. | 1989 | STACCHINI A ;PONZETTO C ;GUERRASIO A ;MARTINOTTI G ;REGE CAMBRIN G ;SCARAVAGLIO P ;ROSSO C ;PIACIBELLO W ;AGLIETTA M ;SAGLIO G | |
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS (TKIS) | 2015 | Sora, F; Autore, F; Alimena, G; Annunziata, M; Avanzini, P; Bocchia, M; Breccia, M; Celesti, F; Chiusolo, P; Crugnola, M; Endri, M; Fava, C; Galimberti, S; Gozzini, A; Iurlo, A; Latagliata, R; Musto, P; Porrini, R; Pregno, R; Cambrin, Gr; Sica, S | |
[Fanconi-Zinsser's disease associated to Lewandowsky-Lutz's disease (author's transl)] | 1981 | LOVISETTO P ;BÜCHI G ;MAIRANO S ;BIARESE V ;ACTIS GC ;ZINA A ;BUNDINO S ;DE MARCHI M | |
Fattori prognostici nel mieloma multiplo. | 1989 | Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede' P; Palumbo A; Pileri A | |
Feasibility of molecular diagnosis of alpha-thalassemia in the evaluation of microcytosis | 1997 | Sivera, P; Roetto, A; Mazza, U; Camaschella, C | |
Fibrinolytic activity in normal and leukemic myeloid differentiation. | 1982 | Ghezzo F; Palumbo A; Pegoraro L | |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials | 2020 | Larocca, Alessandra; Mina, Roberto; Offidani, Massimo; Liberati, Anna Marina; Ledda, Antonio; Patriarca, Francesca; Evangelista, Andrea; Spada, Stefano; Benevolo, Giulia; Oddolo, Daniela; Innao, Vanessa; Cangialosi, Clotilde; Bernardini, Annalisa; Musto, Pellegrino; Amico, Valeria; Fraticelli, Vincenzo; Paris, Laura; Giuliani, Nicola; Falcone, Antonietta Pia; Zambello, Renato; De Paoli, Lorenzo; Romano, Alessandra; Palumbo, Antonio; Montefusco, Vittorio; Hajek, Roman; Boccadoro, Mario; Bringhen, Sara | |
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY | 2014 | Scarfo, L; Quaresmini, G; Ambrosetti, A; Laurenti, L; Rossini, F; Trentin, L; Coscia, M; Orlandi, E; Mannina, D; Torreggiani, A; Rambaldi, A; Semenzato, G; Innocenti, I; Brugiatelli, M; Cuneo, A; Foa, R; Molica, S; Morra, E; Pane, F; Pizzolo, G; Ghia, P | |
FISH-MLL abnormalities in patients in Acute Myeliodblastic Leukemia and association with FLT3 and MLL internal duplication. | 2006 | Giugliano E; Rege-Cambrin G; Scaravaglio P; Diverio D; Serra A; Mancini M; Brunetto V; Ferranti G; Mattioli G; Fava C; Fimognari M; Ulisciani S; Pane F; Lo Coco F; Saglio G. | |
FOUR-YEAR OUTCOME OF 215 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FRONTLINE: A GIMEMA CML WORKING PARTY ANALYSIS | 2014 | Gugliotta, G; Castagnetti, F; Breccia, M; Levato, L; Fava, C; Luciano, L; Zaccaria, A; Rossi, Ar; Usala, E; Gozzini, A; Vigneri, P; Cedrone, M; Tiribelli, M; Abruzzese, E; Avanzini, P; Palandri, F; Soverini, S; Alimena, G; Pane, F; Martinelli, G; Cavo, M; Saglio, G; Baccarani, M; Rosti, G | |
FOXO TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN CML PATIENTS BY BCR-ABL ONCOGENIC SIGNALLING | 2008 | F. Messa; C. Panuzzo; F. Arruga; P. Nicoli; E. Messa; A. Morotti; A. Rotolo; S. Carturan; T. Kalebic; I. Iacobucci; G. Martinelli; E. Bracco; G. Saglio; D. Cilloni | |
FOXO3 TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN ACUTE MYELOID LEUKEMIA PATIENTS | 2008 | Panuzzo C; Arruga F; Messa F; Bracco E; Rotolo A; Nicoli P; Morotti A; Maffè C; Iacobucci I; Martinelli G; Baccarani M; Saglio G; Cilloni D | |
FOXO3 TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN CML PATIENTS BY BCR-ABL ONCOGENIC SIGNALLING | 2008 | Panuzzo C; Messa F; Arruga F; Bernardoni R; Rotolo A; Carturan S; Nicoli P; Morotti A; Marrè C; Iacobucci I; Martinelli G; Baccarani M; Saglio G; Cilloni D | |
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma | 2006 | Foglietta M; Mariani S; Castella B; Coscia M; Boccadoro M; Massaia M | |
FRONT-LINE THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE, OFATUMUMAB (FC-O2) IN YOUNG (<= 65 YRS) AND FIT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. RESULTS OF THE PROSPECTIVE PHASE 2 GIMEMA STUDY LLC0911 | 2017 | Mauro, FR; Molica, S; Zaja, F; Piciocchi, A; Ilariucci, F; Coscia, M; Carella, AM; Re, F; Liberati, AM; Tedeschi, A; Gozzetti, A; Cuneo, A; Cortelezzi, A; Baraldi, A; Del Poeta, G; Musolino, C; Battistini, R; De Propris, MS; Della Starza, I; Raponi, S; Ilari, C; Cafforio, L; Nanni, M; Fazi, P; Vignetti, M; Russo, F; Porrazzo, M; Riemma, C; Specchia, G; Neri, A; Guarini, A; Foa, R | |
Front-line treatment of Philadelphia positive chronic myeloid leukemia withimatinib and interferon-alpha: 5-year outcome | 2008 | Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; GIMEMA Working Party on CML |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile